research use only
Cat.No.S9919
|
In vitro |
DMSO
: 51 mg/mL
(200.55 mM)
Ethanol : 51 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 254.29 | Formula | C11H18N4O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 70132-50-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Ro 03-8799 | Smiles | OC(CN1CCCCC1)C[N]2C=CN=C2[N+]([O-])=O | ||
| In vitro |
Pimonidazole has radio-sensitivity and recovery capacity from radiation-induced damage depend on p53 status of the tumor cell.<sup><a class="sref" href="#s_ref">[3]</a></sup> |
|---|---|
| In vivo |
Pimonidazole can overcome radiation resistance in hypoxiaby melanoma cells, which is enhanced by liposome modification.<sup><a class="sref" href="#s_ref">[2]</a></sup> |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03718650 | Withdrawn | Pancreatic Cancer|Resectable Pancreatic Cancer |
H. Lee Moffitt Cancer Center and Research Institute|Varian Medical Systems |
April 1 2021 | Early Phase 1 |
| NCT03410420 | Suspended | Aortic Aneurysm Thoracic |
University of Maryland Baltimore |
October 1 2018 | Phase 1 |
| NCT03262311 | Completed | Cancer |
Institute of Cancer Research United Kingdom |
November 10 2017 | Not Applicable |
| NCT02624115 | Completed | Colon Rectal Cancer Adenocarcinoma |
University Health Network Toronto |
May 1 2016 | -- |
| NCT02095249 | Active not recruiting | Prostate Cancer |
University Health Network Toronto |
September 2014 | Not Applicable |
| NCT00374517 | Withdrawn | Refractory Pulmonary Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID)|International Tuberculosis Research Center|National Institutes of Health Clinical Center (CC) |
September 5 2006 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.